Results 111 to 120 of about 721 (165)
Some of the next articles are maybe not open access.
Pharmacokinetics of Glucarpidase in Subjects With Normal and Impaired Renal Function
Journal of Clinical Pharmacology, 2008Glucarpidase (formerly known as carboxypeptidase G2 or CPG2) is being evaluated for the adjunctive treatment of patients experiencing, or at risk of, methotrexate toxicity attributable to its delayed elimination. Delayed elimination of methotrexate can occur in patients with methotrexate‐induced renal toxicity.
Marc, Phillips +3 more
exaly +3 more sources
A pooled subgroup analysis of glucarpidase treatment in 86 pediatric, adolescent, and young adult patients receiving high‐dose methotrexate therapy in open‐label trials [PDF]
Pediatric Blood and Cancer, 2023 Acute kidney injury; Glucarpidase; MethotrexateLesió renal aguda; Glucarpidasa; MetotrexatLesión renal aguda; Glucarpidasa; MetotrexatoBackground Delayed methotrexate elimination can occur in patients undergoing high-dose methotrexate cancer treatment ...
Katherine A Janeway +2 more
exaly +3 more sources
Rescue Therapies for AKI in Onconephrology: Rasburicase and Glucarpidase
Seminars in Nephrology, 2022Tumor lysis syndrome (TLS) and high-dose methotrexate (HD MTX) toxicity can present with potentially severe complications, including acute kidney injury, in patients with malignancy. Guidelines for using rasburicase and glucarpidase as rescue therapies for TLS and HD MTX toxicity, respectively, are widely used by clinicians intending to mitigate organ ...
Sheron, Latcha, Chintan V, Shah
openaire +2 more sources
Hospital Pharmacy, 2012
Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing
Dennis J. Cada +3 more
openaire +1 more source
Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing
Dennis J. Cada +3 more
openaire +1 more source
Glucarpidase following high-dose methotrexate: update on development
Expert Opinion on Biological Therapy, 2009Glucarpidase (Carboxypeptidase G2 or Voraxaze) is a recombinant enzyme that belongs to the class of carboxypeptidases which are naturally occurring enzymes. Glucarpidase is able to cleave methotrexate (MTX) into non-cytotoxic metabolites that may help prevent or minimise subsequent toxicities such as renal failure.
Daniel M, Patterson, Siow Ming, Lee
openaire +2 more sources
Glucarpidase for the treatment of life-threatening methotrexate overdose
Drugs of Today, 2012High-dose methotrexate (HDMTX) is widely and safely used in oncology, with adequate measures including vigorous hydration, urine alkalinization and leucovorin rescue. Despite these precautions, some patients still develop HDMTX-induced nephrotoxicity, which leads to delayed methotrexate (MTX) clearance and sustained elevated plasma MTX levels, which ...
Tuffaha, HW, Al Omar, S
openaire +2 more sources